2013
DOI: 10.1136/annrheumdis-2013-204223
|View full text |Cite
|
Sign up to set email alerts
|

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)

Abstract: BackgroundPatients with rheumatoid arthritis (RA) are at increased risk of developing comorbid conditions.ObjectivesTo evaluate the prevalence of comorbidities and compare their management in RA patients from different countries worldwide.MethodsStudy design: international, cross-sectional. Patients: consecutive RA patients. Data collected: demographics, disease characteristics (activity, severity, treatment), comorbidities (cardiovascular, infections, cancer, gastrointestinal, pulmonary, osteoporosis and psyc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

29
463
10
65

Year Published

2015
2015
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 714 publications
(595 citation statements)
references
References 37 publications
(43 reference statements)
29
463
10
65
Order By: Relevance
“…The prevalence of comorbidities in our study was generally in line with previous epidemiologic reports [25]; however, we demonstrated that the number and the type of comorbidity Fig. 3 Multinomial logistic regression analyzing the factors associated with the choice of a specific first-line (a) or second-line (b) bDMARD (ABA or TCZ) compared to TNFi differ among the three different therapeutic agents and may influence the choice of bDMARD treatment.…”
Section: Discussionsupporting
confidence: 90%
See 1 more Smart Citation
“…The prevalence of comorbidities in our study was generally in line with previous epidemiologic reports [25]; however, we demonstrated that the number and the type of comorbidity Fig. 3 Multinomial logistic regression analyzing the factors associated with the choice of a specific first-line (a) or second-line (b) bDMARD (ABA or TCZ) compared to TNFi differ among the three different therapeutic agents and may influence the choice of bDMARD treatment.…”
Section: Discussionsupporting
confidence: 90%
“…Interestingly, after 5 years, up to 41% of patients developed at least one new comorbidity, mainly cardiovascular, neoplastic, or osteoporosis. The high prevalence of comorbid conditions in patients with RA has been confirmed by a number of studies, among which, the COMOrbidities in Rheumatoid Arthritis (COMORA) study [25], a large international, cross-sectional study recruiting 4586 patients, highlighted the high prevalence of comorbidities and related risk factors in patients with RA and the need for an optimization of treatment.…”
Section: Discussionmentioning
confidence: 93%
“…Several population-based studies have validated the benefits of a K-rich diet and K supplementation in the prevention and treatment of hypertension [79][80][81][82]. Though the exact mechanism is not known, several experimental studies have demonstrated the inhibitory effects of serum K on vascular smooth muscle proliferation, reducing macrophage adherence to the vascular wall, arterial thrombosis, free oxygen radicals, and reactive oxygen species [83][84][85]. K ions are also released by the endothelial cells in response to neuro-humoral mediators (sympatheticadrenal and cortisol related mechanisms) and physical forces (such as shear stress) and contribute to endothelium-dependent relaxations.…”
Section: Potassium (K)mentioning
confidence: 99%
“…Despite general recognition that patients with RA are at increased risk of CVD events, there is ample evidence that even well established CVD risk factors such as hypertension and dyslipidemia are not identified and managed consistently in RA populations (6)(7)(8)(9)(10)(11)(12)(13)(14)(15). One strategy to reduce CVD risk in RA is therefore to better identify and manage modifiable risk factors such as smoking, hypertension, obesity and dyslipidemia.…”
Section: Introductionmentioning
confidence: 99%